<DOC>
	<DOCNO>NCT00313508</DOCNO>
	<brief_summary>This randomize , control , multicenter , dose-escalation study fludarabine . Patients randomize 1 2 treatment arm . The purpose study find side effect cause study whether Fludarabine dendritic cell vaccine ( DC vaccine ) increase ability immune system recognize melanoma .</brief_summary>
	<brief_title>Dendritic Cell Vaccination During Lymphoid Reconstruction</brief_title>
	<detailed_description>This dose range study intranodal administration autologous dendritic cell ( DC ) pulse tumor antigen class I peptides derive MART-1 ( 26-35 ) ( 27L ) , gp100 ( 209-217 ( 210M ) , gp100 280-288 ( 288V ) , NY-ESO-1 157-165 ( 165V ) tyrosinase 207-215 well class II MART-1 ( 51-73 ) , NY-ESO-1 ( 119-143 ) , MAGE-3 ( 243-258 ) tyrosinase ( 450-462 ) peptide precede Autologous Lymphocyte Infusion ( ALI ) one two dos Fludarabine . The nine ten amino acid peptide represent HLA-A2 restrict T cell epitopes MART-1 , gp100 , NY-ESO-1 tyrosinase pulse onto autologous dendritic cell produce incubation peripheral blood mononuclear cell obtain apheresis interleukin-4 ( IL-4 ) GM-CSF pulse four helper peptide mature cytokine cocktail include TNF-a , IL-6 , IL-1b PGE2 . Melanoma antigen peptide-pulsed dendritic cell administer total dose 10 million cell four intranodal injection patient chemotherapy-na√Øve metastatic melanoma . DC mature cytokine cocktail pulse class I II peptide inject intranodally , weekly two dos , every two week two dos , total four injection cohort .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Metastatic melanoma measurable disease attempt curative surgical therapy without prior chemotherapy ; adjuvant interferon isolate limb perfusion allow . Tumor tissue must available immunohistochemical analysis , specimen stain MART1/tyrosinase/NYESO1 immunohistochemical staining also stain HMB45 immunohistochemistry , positivity least one entry requirement . Patients must HLAA *0201 positive DNA polymerase chain reaction ( PCR ) analysis . Serum creatinine 2.0 mg/dl less , total bilirubin 2.0 mg/dl less , alanine transaminase/aspartic transaminase ( ALT/AST ) less 3X institutional upper limit normal ( ULN ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients must able understand sign Institutional Review Board ( IRB ) approve informed consent form . Patients must whit blood count ( WBC ) 3000 great , platelet 100,000 great , hemoglobin 9.0 gm/dl . Patients must seropositive EpsteinBarr virus ( EBV ) . Patients unresectable stage III/IV uveal melanoma metastatic mucosal melanoma eligible trial . Patients undergo undergone past month therapy melanoma , include radiation therapy , chemotherapy adjuvant therapy . Have major systemic infection , coagulation disorder , major medical illness ( MI ) cardiovascular respiratory system , document MI last 6 month . Require steroid therapy . Are pregnant lactating . Are known positive hepatitis BsAg , Hepatitis C human immunodeficiency virus ( HIV ) antibody , since cell DC grown laboratory virus contaminate . Have prior history uveitis autoimmune inflammatory eye disease . Have previously receive gp100 209217 ( 210M ) , MART1 2635 ( 27L ) , gp100 280288 ( 288V ) , tyrosinase 207215 NYESO1 157165 ( 165V ) peptide . Have another malignancy cervical carcinomainsitu basal cell /squamous cancer skin , unless undergone curative therapy 5 year ago still free detectable disease . Since trial increase risk immunological impairment , patient follow excluded trial : Hypogammaglobulinemia , Lymphocytopenia , History impair immune response , tuberculosis ( TB ) positive purify protein derivative ( PPD ) unless receive BCG vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
</DOC>